Mylotarg Patient Assistance Program

Key Takeaways

  1. Mylotarg® (gemtuzumab ozogamicin) is a CD33-directed antibody-drug conjugate (ADC) approved for the treatment of CD33-positive acute myeloid leukemia (AML) in eligible adults and pediatric patients.
  2. Mylotarg may be used in combination with chemotherapy or as a single agent, depending on the patient's age, disease status, and treatment indication.
  3. Mylotarg carries an FDA Boxed Warning for hepatotoxicity, including severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS).
  4. Mylotarg is a specialty oncology biologic administered by intravenous infusion. It requires careful monitoring of liver function, blood counts, bleeding, infection, and infusion-related reactions.
  5. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Mylotarg more affordable.

 

Introduction

Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood and bone marrow that requires prompt treatment by an experienced oncology team. Some AML cells express the CD33 protein, allowing targeted therapies to deliver treatment directly to leukemia cells.

Mylotarg is a CD33-directed antibody-drug conjugate approved for certain adults and pediatric patients with CD33-positive acute myeloid leukemia. Depending on the specific indication, it may be used in combination with chemotherapy or as a single-agent treatment for relapsed or refractory disease.

Prescription assistance programs accessed through Prescription Hope may help eligible patients obtain Mylotarg at a more affordable cost.

What Is the Mylotarg Patient Assistance Program?

Understanding Mylotarg Prescription Assistance

Pharmaceutical manufacturers understand that some of their brand-name medications are too expensive for the average American to pay retail.

To help alleviate the financial burden, many manufacturers offer patient assistance programs. These offer qualified patients access to their brand-name medications at affordable rates.

However, some of the programs have been known to require extensive and difficult application processes. Patients have reported feeling overwhelmed, anxious, and frustrated with the process.

Thankfully, Prescription Hope offers a solution.

How Expert Advocates Help Make Mylotarg More Affordable

Personalized Medication Assistance

Prescription Hope offers leukemia medication support services and so much more. Our prescription assistance specialists manage the application process on behalf of our patients from beginning to end.

We handle forms, documents, and signatures, coordinating with healthcare providers and manufacturers, and advocate on your behalf.

Ongoing Patient Support

After a qualified patient is approved, our team of patient advocates continues to handle administrative tasks, including document updates, issue resolution, yearly renewals, program monitoring, and even refill scheduling.

Mylotarg Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$10,573.55

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Cancer Treatment Costs

Our support services help patients save on their monthly costs. Our brand-name med cost assistance is a simple $70.00 per month, per medication.

And if we can’t help you save, then you don’t pay!

Mylotarg Patient Assistance Eligibility

General Eligibility Requirements

To determine Mylotarg eligibility, patients can enroll with Prescription Hope.

While each program has its own unique requirements, all programs maintain standards in several general categories. Those include:

Income: All programs maintain a specific range of income for qualification.

Insurance: Every program sets a level or status of insurance coverage that is acceptable. Some require a patient to have no insurance, while others allow for some form of insurance coverage.

Prescription: All programs require a patient to have a valid prescription for their medication.

U.S. Residency: All patients must be legal U.S. residents to qualify.

Simple Enrollment With Expert Support

Getting Started With Enrollment

To enroll in Mylotarg assistance, patients can follow Prescription Hope’s 6 simple steps:

  1. Submit Information: Our online form can be completed in a few minutes from the comfort of your home, or wherever you are.
  2. Advocate Contact: A patient advocate will contact you in 1-2 business days.
  3. Document Collection: Following a quick prequalification, our team will collect needed documents.
  4. Provider Coordination: We connect with your healthcare provider to secure vital signatures.
  5. Program Submission: Our team completes your application packet, submits it, and continues to follow up with the manufacturer.
  6. Medication Delivery: Once approved, qualified patients can typically expect to receive their medications within 2 weeks, though shipping times may vary. All medication shipments come directly from the manufacturer and arrive at your home or doctor’s office.

Understanding Mylotarg

How Mylotarg Works

Mylotarg contains gemtuzumab ozogamicin, a CD33-directed antibody-drug conjugate (ADC).

The monoclonal antibody binds specifically to the CD33 antigen, which is expressed on the surface of most AML blast cells. After binding, the antibody-drug complex is internalized into the leukemia cell.

Following internalization, the linker is hydrolyzed intracellularly, releasing N-acetyl gamma calicheamicin, which binds DNA and induces double-strand breaks, leading to cell cycle arrest and apoptotic cell death.

This targeted delivery helps concentrate the cytotoxic agent within CD33-positive leukemia cells while limiting exposure to non-target cells.

What Conditions Does Mylotarg Treat?

Mylotarg is FDA-approved for the treatment of CD33-positive acute myeloid leukemia (AML) in:

  • Adults with newly diagnosed CD33-positive AML, used in combination with standard chemotherapy
  • Adults with relapsed or refractory CD33-positive AML as a single agent
  • Pediatric patients 1 month of age and older with newly diagnosed CD33-positive AML, used in combination with chemotherapy
  • Pediatric patients 2 years of age and older with relapsed or refractory CD33-positive AML as a single agent

Treatment is indicated only for patients with CD33-positive acute myeloid leukemia, as determined by appropriate diagnostic evaluation.

Benefits of Treatment

For appropriate patients with CD33-positive AML, Mylotarg may:

  • Target leukemia cells expressing the CD33 antigen
  • Have demonstrated improved event-free survival in appropriate adults with newly diagnosed CD33-positive AML when used in combination with chemotherapy
  • Induce remission in certain patients with relapsed or refractory AML.
  • Provide a targeted treatment option for both adults and eligible pediatric patients.
  • Deliver chemotherapy directly to leukemia cells through antibody-drug conjugate technology.

Treatment outcomes vary based on disease characteristics, patient age, prior therapies, and overall clinical status.

Important Safety Information and Side Effects

Mylotarg carries an FDA Boxed Warning for:

  • Hepatotoxicity, including severe, life-threatening, and sometimes fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS)

The risk is increased in patients who undergo hematopoietic stem cell transplantation (HSCT), receive higher cumulative doses, or have pre-existing liver impairment.

Contraindications

The FDA Prescribing Information lists no contraindications for Mylotarg.

The most commonly reported adverse reactions include:

  • Hemorrhage (bleeding)
  • Infection
  • Fever (pyrexia)
  • Fatigue
  • Nausea
  • Vomiting
  • Constipation
  • Mucositis (mouth sores)
  • Headache
  • Rash
  • Abdominal pain

Common laboratory abnormalities include:

  • Thrombocytopenia
  • Neutropenia
  • Anemia
  • Elevated liver enzymes
  • Hyperbilirubinemia

Patients should notify their healthcare provider if they experience severe bleeding, fever, signs of infection, worsening abdominal pain, or other concerning symptoms.

Patients should discuss the following risks with their healthcare provider:

  • Hepatotoxicity and hepatic veno-occlusive disease (VOD/SOS)
  • Infusion-related reactions, including severe hypersensitivity reactions
  • Hemorrhage
  • Prolonged thrombocytopenia
  • Severe neutropenia and infection
  • Tumor lysis syndrome
  • QT interval prolongation
  • Embryo-fetal toxicity
  • Persistent or severe infusion-related reactions that may require interruption or permanent discontinuation of therapy

Patients require careful monitoring throughout treatment, particularly liver function tests and complete blood counts.

Mylotarg may cause fetal harm when administered during pregnancy. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. Patients should notify their healthcare provider immediately if pregnancy occurs during therapy.

Patients should not breastfeed during treatment and for at least 1 month after the final dose because of the potential for serious adverse reactions in a breastfed child.

Healthcare providers should review all medications before treatment. Particular attention should be given to:

  • Medications known to prolong the QT interval
  • Other hepatotoxic medications
  • Other myelosuppressive therapies

Patients should inform their healthcare provider about all prescription medications, over-the-counter products, vitamins, and herbal supplements before starting treatment.

Mylotarg is administered by intravenous infusion over 2 hours. Dosage is based on body surface area (BSA), the treatment indication, and whether it is used alone or with chemotherapy. Premedication with corticosteroids, acetaminophen, and an antihistamine is recommended to reduce infusion-related reactions. Patients should be monitored during the infusion and for at least 1 hour after completion of each infusion. Liver function tests and complete blood counts should be monitored before and throughout treatment.

Access to Multiple Medications

Support Beyond Mylotarg

Patients needing multiple medication assistance programs can still enroll in Prescription Hope’s medication access services.

Whether you qualify for one or many, our service rate remains a simple $70.00 per month, per med.

Why Choose Prescription Hope

Patient-Focused Medication Support

For 20 years, Prescription Hope’s team of patient advocates has provided support and advocacy on behalf of Americans across the nation.

Simplified Access to Prescription Medications

Our monthly service fee of $70.00 per med means patients receive all of our services, both during the application process and throughout their medication access journey.

Ongoing Prescription Assistance

Our long-term medication support means patients receive our ongoing services, including document updates, yearly renewals, issue resolution, refill scheduling, and more.

If you’re looking to access the Mylotarg Patient Assistance Program, then be sure to enroll with Prescription Hope today and find out how we can help you save!

 

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!